Dipeptidyl peptidase-4 (DPP4) enzyme inhibition has been reported to increase plasma glucagon-like peptide-1 (GLP-1) level for controlling postprandial glucose concentration. A prominent GLP-1 level in DPP4-deficient rats contributed to the resistance of endotoxemia and myocardial infarction. DPP4 deficiency also increased the capability against H2O2-induced stress in cardiomyocyte. However, long term effect of loss DPP4 activity on cardiac performance remained unclear. We used abdominal aortic banding (AAB) to induce pressure overload in wild-type and DPP4-deficient rats, and investigated the progression of heart failure. Cardiac histology and function were determined. Blood sample was collected for the plasma biochemical marker measuremen...
The introduction of incretin hormone-based therapies represents a novel therapeutic strategy, since ...
Free fatty acids deposition in non-adipose tissues such as the heart is a characteristic of insulin ...
Dipeptidyl-peptidase-4 (DPP4) inhibitors are novel medicines for diabetes. The SAVOR-TIMI-53 clinica...
Dipeptidyl peptidase-4 (DPP4) enzyme inhibition has been reported to increase plasma glucagon-like p...
Dipeptidyl peptidase-4 (DPP4) enzyme inhibition has been reported to increase plasma glucagon-like p...
Dipeptidyl peptidase-4 (DPP4) enzyme inhibition has been reported to increase plasma glucagon-like p...
Glucagon-like peptide-1 (GLP-1) is rapidly cleaved by widely expressed dipeptidyl peptidase-4 (DPP4)...
Apart from the antihyperglycemic effects, DPP4 inhibitors and GLP-1 molecules are involved in the pr...
BACKGROUND: Uremic cardiomyopathy contributes substantially to mortality in chronic kidney disease (...
Dipeptidyl peptidase-4 (DPP-4) inhibitors not only improve impaired glucose tolerance in diabetes, b...
<p>DPP4 activity of (A) total heart and (B) cardiomyocyte protein were measured in wild-type and DPP...
cleaved by dipeptidyl peptidase-4 (DPP-4) to GLP-1 (9-36)amide. We examined whether chemical inhibit...
Uremic cardiomyopathy contributes substantially to mortality in chronic kidney disease (CKD) patient...
AbstractThe purpose of the current study was to test the hypothesis that the dipeptidyl peptidase IV...
Background: Progressive remodeling after myocardial infarction (MI) is a leading cause of morbidity ...
The introduction of incretin hormone-based therapies represents a novel therapeutic strategy, since ...
Free fatty acids deposition in non-adipose tissues such as the heart is a characteristic of insulin ...
Dipeptidyl-peptidase-4 (DPP4) inhibitors are novel medicines for diabetes. The SAVOR-TIMI-53 clinica...
Dipeptidyl peptidase-4 (DPP4) enzyme inhibition has been reported to increase plasma glucagon-like p...
Dipeptidyl peptidase-4 (DPP4) enzyme inhibition has been reported to increase plasma glucagon-like p...
Dipeptidyl peptidase-4 (DPP4) enzyme inhibition has been reported to increase plasma glucagon-like p...
Glucagon-like peptide-1 (GLP-1) is rapidly cleaved by widely expressed dipeptidyl peptidase-4 (DPP4)...
Apart from the antihyperglycemic effects, DPP4 inhibitors and GLP-1 molecules are involved in the pr...
BACKGROUND: Uremic cardiomyopathy contributes substantially to mortality in chronic kidney disease (...
Dipeptidyl peptidase-4 (DPP-4) inhibitors not only improve impaired glucose tolerance in diabetes, b...
<p>DPP4 activity of (A) total heart and (B) cardiomyocyte protein were measured in wild-type and DPP...
cleaved by dipeptidyl peptidase-4 (DPP-4) to GLP-1 (9-36)amide. We examined whether chemical inhibit...
Uremic cardiomyopathy contributes substantially to mortality in chronic kidney disease (CKD) patient...
AbstractThe purpose of the current study was to test the hypothesis that the dipeptidyl peptidase IV...
Background: Progressive remodeling after myocardial infarction (MI) is a leading cause of morbidity ...
The introduction of incretin hormone-based therapies represents a novel therapeutic strategy, since ...
Free fatty acids deposition in non-adipose tissues such as the heart is a characteristic of insulin ...
Dipeptidyl-peptidase-4 (DPP4) inhibitors are novel medicines for diabetes. The SAVOR-TIMI-53 clinica...